Engineering of the high-affinity chemokine CXCL13 to screen CXCR5 antagonists to treat cancer and autoimmune diseases
Ramu M, Rosenberg E, Kartz S, Foss F, Lolis E. Engineering of the high-affinity chemokine CXCL13 to screen CXCR5 antagonists to treat cancer and autoimmune diseases. Biophysical Journal 2023, 122: 474a. DOI: 10.1016/j.bpj.2022.11.2542.Peer-Reviewed Original Research